1. Trade Issues are Key as SOCMA Members Head to The Hill

    We’re just two weeks away from SOCMA’s 8th Annual Washington Fly-In, and talk of passing Trade Promotion Authority (TPA) is heating up on Capitol Hill. Just as it did in 2014, this year’s event – set for April 21-22 – appears to coincide nicely with movement on a couple of SOCMA’s top priority issues, including trade.
  2. The Chemical Industry has Families, Too

    If you have been reading the latest opinion pieces on the Frank R. Lautenberg for Chemical Safety in the 21st Century Act, S.697, you might think there is a conspiracy by the chemical industry to avoid being regulated by weakening the Toxic Substances Control Act (TSCA). The thinking is that since S. 697 is an industry-backed bill it must be inherently bad and deregulatory in nature, so as to perpetuate commercialization of nasty chemicals and facilitate delays at EPA. To make matters worse, critics think that by strengthening preemption of EPA decisions on the states, they (the states) will not be able to adequately protect their citizens. The consequence would be that families and children would be at greater risk from exposures to chemicals than they are under the status quo.
  3. AMPAC’s Christine Roy Recognized as 2015 STEP Award Emerging Leader

    Christine Roy is passionate about her job as a production manager at SOCMA member company AMPAC Fine Chemicals. Because of her passion and dedication, she was recently recognized as a 2015 STEP Ahead Award Emerging Leader by The Manufacturing Institute. This category represents young women who are the future of the industry and have demonstrated exceptional accomplishments at just the beginning of their careers.
  4. FDA to Use Metrics Initiative to Improve Drug Quality throughout Supply Chain

    Combating drug quality and supply shortages are ongoing concerns for stakeholders throughout the pharmaceutical supply chain, including members of SOCMA’s Bulk Pharmaceuticals Task Force (BPTF). As a means to address these concerns, the U.S. Food and Drug Administration (FDA) is working with the pharmaceutical supply chain on a new Quality Metrics Initiative (QMI). This new initiative, which has been in the works for several years, was a key topic of discussion during the recent DCAT Week 2015 in New York.
  5. ChemStewards Educating Members about Benefits of New Optimization Portal

    Last October SOCMA launched a new ChemStewards® Portal as part of the 2014 ChemStewards Optimization Project. This portal is an efficient environmental, health, safety and security (EHS&S) management system that allows our members to save time and effort by having all ChemStewards and related EHS&S documents in a centralized, web-based repository. 
  6. 2015 Global Chemical Regulations Conference & Expo

    Remarks by Lawrence D. Sloan, President & CEO, SOCMA, 2015 GlobalChem Conference & Expo, Hilton Baltimore, Baltimore, MD - Good morning everyone and welcome to Day Two of this year’s Global Chemical Regulations Conference.  As Bill mentioned, my name is Larry Sloan and I am President and CEO of the Society of Chemical Manufacturers & Affiliates.  It is a pleasure to be with you this morning and open today’s proceedings.
  7. SOCMA Committed to Strengthening Nation’s Workforce

    The Society of Chemical Manufacturers and Affiliates (SOCMA) is committed to playing a role in strengthening our nation’s workforce. Our Chemical Process Operator Training (CPOT) program is designed to provide the next generation of chemical/process operators with basic skills they need to secure good paying jobs and opportunities for job advancement as they navigate their careers. But it all starts with a solid foundation of learning.
  8. Where it all begins – the TSCA Pre-Manufacturing Notice (PMN)

    Complying with the Toxic Substances Control Act, our nation’s chemical control law, can be complicated and costly. Under TSCA section 16(a), the Environmental Protection Agency (EPA) can impose penalties of up to $37,500 each day, so the consequences of non-compliance can be quite serious.
  9. BPTF Voices Concern to FDA about Reduction of Domestic Facility Inspection Frequency

    SOCMA’s Bulk Pharmaceuticals Task Force has long been an advocate and supporter of the Food and Drug Administration’s (FDA) Generic Drug User Fee (GDUFA) program and its goal to consistently perform risk-based inspections of both U.S. and foreign drug manufacturing facilities. But concerns were recently raised when a memo from the Department of Health and Human Services disclosed a 40 percent decrease in the number of inspections of U.S. drug facilities in 2014 and 2015 – a move that could significantly impact the generic active pharmaceutical ingredient (API) manufacturers the Task Force represents.

  10. Bulk Pharmaceuticals Task Force Alarmed at Reduction in Compliance Inspections

    Washington, D.C. – The Bulk Pharmaceuticals Task Force (BPTF), which is an affiliate of the Society of Chemical Manufacturers and Affiliates (SOCMA), issued a letter on Tuesday to the Food and Drug Administration (FDA) asking that the agency ensure the frequency of inspections for any domestic Active Pharmaceutical Ingredient (API) manufacturer remains consistent.
  11. SOCMA's Bulk Pharmaceuticals Task Force Welcomes Waiver for U.S. API Imports to Europe

    Washington, DC – The Bulk Pharmaceuticals Task Force (BPTF) today hailed an announcement from European officials granting U.S. drug makers an exemption from new export requirements, thereby ensuring a continued supply of safe drugs into the EU from the U.S.
  12. Could Sequestration Derail Generic Drug User Fee Program?

    With sequestration looming, SOCMA’s Bulk Pharmaceuticals Task Force is concerned the program it worked years to bring about – Generic Drug User Fees (GDUFA) – could be derailed by budget cuts set to take effect March 1. GDUFA was signed into law by President Obama in July and took effect in October.
  13. SOCMA’s Bulk Pharmaceuticals Task Force Hails Signing of FDA Reform Act into Law

    Washington, DC – In a major victory for the American people, President Obama today signed the Food and Drug Administration's user fee bill into law, making it possible for the federal government to speed approval of lifesaving medicines, reduce drug shortages and improve the quality and availability of drugs in the U.S.
  14. SOCMA’s Bulk Pharmaceuticals Task Force Asks Congress to Increase Inspections of Foreign Drug Manufacturing Facilities

    Washington, DC – The Bulk Pharmaceuticals Task Force (BPTF), an affiliate organization of the Synthetic Organic Chemical Manufacturers Association (SOCMA) testified today on the Food & Drug Administration’s inadequate inspection regime for foreign manufacturers of drug ingredients.  The testimony was before the House Energy & Commerce Committee’s Subcommittee on Oversight and Investigation.
Page 35 of 35First   Previous   26  27  28  29  30  31  32  33  34  [35]  Next   Last   
Return Home